at Harvard Medical School. The company is using the two professors’ method for developing highly targeted drugs for cancer and other diseases based on nano-sized particles, which BIND has named Accurins.
These microscopic particles are meant to ferry chemotherapies and other treatments directly to diseased cells while avoiding healthy ones. The idea is that the particles are so tiny that they can evade detection by the immune system, but then accumulate at the diseased cell and achieve higher drug concentrations than would be possible with a larger molecule.
BIND’s research is currently supported in part by the MIT-Harvard Center for Cancer Nanotechnology, which in turn is part of a $144 million investment by the National Cancer Institute in nanotechnology research. It also has $25 million in funding from Rusnano,
Pages: Page 1, Page 2, Page 3
Author: Catherine Arnst
Catherine Arnst is an award- winning writer and editor specializing in science and medicine. Catherine was Senior Writer for medicine at BusinessWeek for 13 years, where she wrote numerous cover stories and wrote extensively for the magazine’s website, including contributing to two blogs. She followed a broad range of issues affecting medicine and health and held primary responsibility for covering the battle in Washington over health care reform. Catherine has also written for the Boston Globe, U.S. News & World Report and The Daily Beast, and was Director of Content Development for the health practice at Edelman Public Relations for two years. Prior to joining BusinessWeek she was the London-based European Science Correspondent for Reuters News Service. She won the 2004 Business Journalist of the Year award from London’s World Leadership Forum, and in 2003 was the first recipient of the ACE Reporter Award from the European School of Oncology for her five-year body of work on cancer. She holds a bachelor’s degree in journalism from Boston University.
View all posts by Catherine Arnst
